Profile data is unavailable for this security.
About the company
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
- Revenue in GBP (TTM)4.27bn
- Net income in GBP230.85m
- Incorporated1937
- Employees18.00k
- LocationSmith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
- Phone+44 207 401 7646
- Fax+44 207 930 3353
- Websitehttps://www.smith-nephew.com/
Mergers & acquisitions
| Acquired company | SN.:LSE since announced | Transaction value |
|---|---|---|
| Cartiheal 2009 Ltd | 14.14% | 330.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amplifon SpA | 1.96bn | 135.96m | 5.09bn | 14.38k | 37.33 | 5.31 | 13.61 | 2.60 | 0.7153 | 0.7153 | 10.27 | 5.03 | 0.6229 | 21.46 | 10.96 | 161,594.30 | 4.33 | 4.31 | 6.53 | 5.81 | 24.56 | 59.01 | 6.95 | 7.28 | 0.3992 | 6.12 | 0.5921 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| Ypsomed Holding AG | 490.50m | 70.09m | 5.10bn | 2.30k | 72.72 | 9.23 | 37.17 | 10.39 | 5.74 | 5.74 | 40.18 | 45.26 | 0.5587 | 5.40 | 4.96 | 238,875.00 | 7.98 | 4.41 | 12.40 | 6.81 | 34.47 | 27.26 | 14.29 | 7.38 | 0.5967 | 20.89 | 0.293 | 20.50 | 10.25 | 3.86 | 52.83 | 5.44 | 8.64 | 29.46 |
| Demant A/S | 2.52bn | 298.72m | 7.05bn | 21.50k | 23.58 | 6.52 | -- | 2.79 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Smith & Nephew plc | 4.27bn | 230.85m | 10.16bn | 18.00k | 43.98 | 2.58 | 13.93 | 2.38 | 0.2643 | 0.2643 | 4.89 | 4.51 | 0.5535 | 0.7128 | 4.30 | 231,431.50 | 2.99 | 4.10 | 3.62 | 4.99 | 69.04 | 71.39 | 5.41 | 8.02 | 1.11 | 5.48 | 0.4125 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | 1.85 |
| BioMerieux SA | 3.20bn | 346.10m | 10.69bn | 14.65k | 30.99 | 3.27 | 18.00 | 3.34 | 3.46 | 3.46 | 32.04 | 32.80 | 0.7356 | 1.82 | 5.63 | 259,811.60 | 7.71 | 9.30 | 9.57 | 12.31 | 55.72 | 56.51 | 10.48 | 12.38 | 1.20 | 236.14 | 0.1258 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sartorius AG | 2.81bn | 65.30m | 13.92bn | 14.14k | 170.56 | 4.93 | 32.18 | 4.95 | 1.14 | 1.14 | 49.17 | 39.29 | 0.3934 | 1.75 | 9.19 | 228,602.70 | 1.51 | 8.21 | 2.05 | 11.83 | 44.17 | 50.93 | 3.84 | 14.15 | 1.05 | 2.20 | 0.5482 | 19.59 | -18.66 | 16.74 | -69.74 | 7.74 | 19.14 | 3.66 |
| Sartorius Stedim Biotech SA | 2.31bn | 142.38m | 14.71bn | 10.38k | 100.29 | 4.50 | 38.29 | 6.37 | 1.79 | 1.79 | 29.22 | 39.95 | 0.4145 | 1.75 | 8.84 | 257,644.00 | 2.61 | 11.87 | 3.04 | 15.12 | 41.82 | 50.96 | 6.31 | 17.44 | 1.03 | 2.95 | 0.4266 | 18.73 | -20.53 | 18.02 | -64.65 | 8.28 | 21.82 | 3.90 |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 16 Feb 2024 | 45.46m | 5.20% |
| Cevian Capital ABas of 02 Jul 2024 | 43.90m | 5.02% |
| Wellington Management Co. LLPas of 31 Dec 2020 | 42.67m | 4.88% |
| The Vanguard Group, Inc.as of 02 Sep 2024 | 37.04m | 4.24% |
| Norges Bank Investment Managementas of 02 Sep 2024 | 27.57m | 3.15% |
| Norges Bank Investment Management (UK)as of 28 Jun 2024 | 26.70m | 3.05% |
| BlackRock Fund Advisorsas of 02 Sep 2024 | 21.23m | 2.43% |
| Walter Scott & Partners Ltd.as of 02 Sep 2024 | 19.25m | 2.20% |
| UBS Asset Management (UK) Ltd.as of 02 Sep 2024 | 16.70m | 1.91% |
| Legal & General Investment Management Ltd.as of 02 Sep 2024 | 16.04m | 1.84% |
